Stocks Health care ACTU
NASDAQ · Health careActuate Therapeutics, Inc. (ACTU)
It posted a net loss of $20.5M. At June 30, 2026 it held $4.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Actuate Therapeutics, Inc. does
Actuate Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACTU.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$22.2M | -$1.06 | n/a |
| 2024 | n/a | -$27.3M | -$3.26 | n/a |
| 2024 | n/a | -$24.7M | -$17.24 | n/a |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Actuate Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026
- July 17, 2026
- May 22, 2026
- May 14, 2026
- May 14, 2026
- May 11, 2026
- May 6, 2026Additional proxy material DEFA14A
- May 6, 2026
- April 22, 2026Passive stake changed SCHEDULE 13G/A
- April 9, 2026
Insider trades
What the people running Actuate Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 14, 2026 | Schmitt Daniel MPresident, CEO and Director, Director | Exercised options | 272,056 | - |
| August 14, 2026 | Schmitt Daniel MPresident, CEO and Director, Director | Shares withheld for tax | 120,521 | $121.7K |
Who owns ACTU
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Aaron G.L. Fletcher13D, may seek influence with 23 related filers | 49.8% | June 30, 2025 |
| Voss Capital, LP13G, passive with 4 related filers | 7.7% | April 22, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 301,716 shares in total, about $205.2K at the last price.
| Holder | Shares |
|---|---|
| Schmitt Daniel MPresident, CEO and Director, Director | 301,716 |
Questions about ACTU
What does Actuate Therapeutics, Inc. do?
Actuate Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACTU.
Is Actuate Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $20.5M.
When did Actuate Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.
Similar companies
Compare ACTU with
Follow ACTU
Get an email when Actuate Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ACTU: get an email when it filesWhere the numbers come from
Financial figures are the values Actuate Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.